Back

GIPC1 intermediate-length repeat expansion in amyotrophic lateral sclerosis

Muto, K.; Tachibana, K.; Miyamoto, R.; Kuwano, Y.; Kihara, N.; Yamazaki, H.; Osaki, Y.; Banzai, S.; Ueno, H.; Fukumoto, T.; Kamada, M.; Keyoumu, N.; Matsui, N.; Fujita, K.; Nakamori, M.; Yamazaki, Y.; Maruyama, H.; Izumi, Y.; Morino, H.

2025-05-23 neurology
10.1101/2025.05.22.25328088 medRxiv
Show abstract

Repeat expansion diseases, particularly those involving GC-rich motifs, have been increasingly recognized as contributors to neurological and neuromuscular disorders. Amyotrophic lateral sclerosis (ALS) has been linked to several such expansions, including intermediate-length repeats in genes implicated in oculopharyngodistal myopathy (OPDM). To investigate the possible involvement of CGG repeat expansions in ALS, 424 ALS patients and 312 controls of Japanese descent were screened for expansions in five genes associated with repeat expansion disorders, namely GIPC1, RILPL1, FMR1, AFF2, and NUTM2BAS1. Repeat-primed PCR and fragment analysis revealed that four ALS patients exhibited abnormal CGG expansions in GIPC1 (33-55 repeats), whereas two control individuals harbored expanded alleles (67 and 83 repeats). No expansions in the other genes were detected. Long-read sequencing confirmed repeat sizes and showed sequence instability. Histopathological analysis of ALS patients with GIPC1 expansion demonstrated classical ALS pathology, including phosphorylated TDP-43-positive inclusions. RNA fluorescence in situ hybridization revealed nuclear foci containing GIPC1 repeat RNA exclusively in ALS patients with GIPC1 expansions, suggesting RNA-mediated toxicity. These findings indicate that a subset of ALS patients present with intermediate CGG expansions in GIPC1, which may represent a novel pathogenic mechanism analogous to other noncoding repeat disorders. Given that GIPC1 full expansions are associated with OPDM, these results support the hypothesis of a pathological continuum between neurodegeneration and myopathy driven by repeat length and sequence context. Nonetheless, further investigations into the potential of GIPC1 CGG expansions as genetic risk factors or modifiers in ALS are warranted.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Acta Neuropathologica Communications
81 papers in training set
Top 0.1%
12.7%
2
Frontiers in Neurology
91 papers in training set
Top 0.4%
12.4%
3
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.1%
10.1%
4
Neurobiology of Disease
134 papers in training set
Top 0.6%
8.4%
5
Human Molecular Genetics
130 papers in training set
Top 0.8%
3.6%
6
Brain
154 papers in training set
Top 2%
2.7%
50% of probability mass above
7
Muscle & Nerve
10 papers in training set
Top 0.1%
2.7%
8
Acta Neuropathologica
51 papers in training set
Top 0.4%
2.7%
9
Molecular Neurodegeneration
49 papers in training set
Top 0.3%
2.6%
10
Journal of Neurology
26 papers in training set
Top 0.3%
2.6%
11
Scientific Reports
3102 papers in training set
Top 45%
2.6%
12
European Journal of Neurology
20 papers in training set
Top 0.2%
2.1%
13
Molecular Neurobiology
50 papers in training set
Top 0.3%
1.9%
14
Movement Disorders
62 papers in training set
Top 0.6%
1.9%
15
Journal of Neurology, Neurosurgery & Psychiatry
29 papers in training set
Top 0.6%
1.8%
16
Neurology
44 papers in training set
Top 0.8%
1.7%
17
Disease Models & Mechanisms
119 papers in training set
Top 1%
1.7%
18
Annals of Clinical and Translational Neurology
29 papers in training set
Top 0.8%
1.2%
19
Brain Communications
147 papers in training set
Top 2%
1.2%
20
Annals of Neurology
57 papers in training set
Top 2%
1.1%
21
Journal of the Neurological Sciences
17 papers in training set
Top 0.6%
0.9%
22
PLOS ONE
4510 papers in training set
Top 64%
0.9%
23
Neurobiology of Aging
95 papers in training set
Top 2%
0.9%
24
Journal of Parkinson's Disease
13 papers in training set
Top 0.3%
0.9%
25
EMBO Molecular Medicine
85 papers in training set
Top 4%
0.8%
26
Heliyon
146 papers in training set
Top 6%
0.7%
27
Science Translational Medicine
111 papers in training set
Top 6%
0.7%
28
Mitochondrion
11 papers in training set
Top 0.2%
0.7%
29
Frontiers in Cellular Neuroscience
79 papers in training set
Top 1%
0.7%
30
Frontiers in Aging Neuroscience
67 papers in training set
Top 3%
0.7%